Overview

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants

Status:
COMPLETED

Trial end date:
2025-09-11

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) of high dose of BMS-986278 in healthy participants and to assess the effect of BMS-986278 on the ECG intervals in healthy participants.

Phase:

PHASE1

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Moxifloxacin